Trial Profile
A Study to Evaluate the Effect of Aflibercept on Pigment Epithelial Detachment (PED) Morphology in Patients With Neovascular Age Related Macular Degeneration With PED Refractory to Monthly Intravitreal Bevacizumab or Ranibizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Mar 2016
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacodynamics
- 07 Mar 2016 New trial record